Comparing Metagenomi (NASDAQ:MGX) and UCB (OTCMKTS:UCBJY)

UCB (OTCMKTS:UCBJY) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Volatility and Risk

UCB has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for UCB and Metagenomi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UCB	0	1	0	1	3.00
Metagenomi	1	0	3	1	2.80

Metagenomi has a consensus price target of $10.00, suggesting a potential upside of 471.43%. Given Metagenomi’s higher possible upside, analysts plainly believe Metagenomi is more favorable than UCB.

Earnings & Valuation

This table compares UCB and Metagenomi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UCB	$6.66 billion	N/A	$1.15 billion	N/A	N/A
Metagenomi	$30.91 million	2.12	-$78.06 million	($2.40)	-0.73

UCB has higher revenue and earnings than Metagenomi.

Profitability

This table compares UCB and Metagenomi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UCB	N/A	N/A	N/A
Metagenomi	-287.06%	-43.19%	-31.06%

Summary

UCB beats Metagenomi on 7 of the 9 factors compared between the two stocks.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.